Potassium%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCl) is an essential electrolyte used to prevent or treat hypokalemia. It is available in oral and intravenous (IV) formulations. ## Primary Indications * Prevention and treatment of hypokalemia. ## Adult Dosing * **Oral:** * **Prevention:** 10-20 mEq (milliequivalents) per day, divided into 1-2 doses. * **Treatment:** 40-100 mEq per day, divided into 2-4 doses. * **Maximum single oral dose:** Typically 20 mEq. Higher doses may be given cautiously in divided doses under close monitoring. * **Maximum daily oral dose:** Generally not to exceed 200 mEq without extreme caution and close monitoring due to risk of hyperkalemia. * **Intravenous (IV):** Dosing is highly individualized and depends on serum potassium levels and clinical status. * **General treatment:** 10-20 mEq/hour infusion. * **Severe hypokalemia (serum K < 2.5 mEq/L) or inability to tolerate oral intake:** May require higher infusion rates (e.g., up to 40 mEq/hour) and continuous ECG monitoring. * **Maximum single IV dose:** Up to 40 mEq in a single infusion, but often limited by concentration and infusion rate. * **Maximum daily IV dose:** Typically not to exceed 200 mEq in 24 hours, but can be higher in critical care settings with intense monitoring. * **Concentration:** IV solutions should generally not exceed 40 mEq/L in peripheral IV lines and 80 mEq/L in central venous lines to minimize phlebitis. Higher concentrations (e.g., up to 100 mEq/L) may be used in critical situations via central line with continuous ECG monitoring, but this is a high-risk practice. ## Pediatric Dosing * **Oral:** * **Prevention:** 1-2 mEq/kg/day, maximum 20 mEq/day. * **Treatment:** 2-5 mEq/kg/day, divided into 2-4 doses, maximum 20 mEq/dose and 100 mEq/day. * **Intravenous (IV):** Dosing is highly individualized. * **Usual range:** 0.5-1 mEq/kg/hour infusion rate. * **Maximum infusion rate:** Generally not to exceed 0.5-1 mEq/kg/hour (up to 20 mEq/hour in neonates) without continuous ECG monitoring. Higher rates (e.g., up to 2 mEq/kg/hour, maximum 40 mEq/hour) may be used in severe hypokalemia under expert supervision and continuous monitoring. * **Maximum concentration:** Peripheral IV: 40 mEq/L. Central IV: 80 mEq/L. ## Dose Adjustments * **Renal Impairment:** Use with extreme caution. Dose reduction is necessary, and serum potassium should be closely monitored to prevent hyperkalemia. * **Hepatic Impairment:** No specific dose adjustment, but monitor electrolytes closely. ## Contraindications * Hyperkalemia. * Conditions that predispose to hyperkalemia (e.g., severe renal impairment, untreated Addison's disease, acute dehydration, extensive tissue injury). * Certain medications (e.g., potassium-sparing diuretics, ACE inhibitors, ARBs in patients with renal impairment). ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal discomfort, flatulence. * **Serious:** Hyperkalemia (muscle weakness, paresthesias, cardiac arrhythmias, cardiac arrest), esophageal or gastric irritation/perforation (especially with enteric-coated tablets), venous irritation, phlebitis (IV). ## Key Drug Interactions * **Potassium-sparing diuretics (e.g., spironolactone, amiloride):** Increased risk of hyperkalemia. * **ACE inhibitors and ARBs:** Increased risk of hyperkalemia, especially in patients with renal impairment. * **NSAIDs:** May decrease potassium excretion, increasing risk of hyperkalemia. * **Digoxin:** Hypokalemia enhances digoxin toxicity; hyperkalemia reduces it. * **Sodium Polystyrene Sulfonate:** Decreases absorption of KCl; monitor electrolytes. ## Monitoring * **Serum Potassium:** Frequently monitor serum potassium levels, especially during IV administration, with dose changes, or in patients with renal impairment. * **Renal Function:** Monitor serum creatinine and BUN. * **ECG:** Consider ECG monitoring for patients receiving rapid IV infusions, those with severe hypokalemia, or those at high risk for arrhythmias. * **Signs and Symptoms of Hypokalemia/Hyperkalemia:** Monitor for muscle weakness, fatigue, cramps, arrhythmias, and changes in mental status. ## Clinical Pearls * Oral KCl should be taken with meals or a full glass of water to minimize gastrointestinal upset. * Crushing or chewing extended-release formulations can lead to rapid potassium release, increasing the risk of GI irritation and hyperkalemia. * IV KCl must be diluted and infused slowly to prevent severe local and systemic reactions, including cardiac arrest. * Always verify the concentration and infusion rate of IV potassium carefully. * Dosing of IV potassium in pediatric patients, especially neonates, requires extreme caution and often specialized protocols. *** **Educational Disclaimer:** This information is intended for clinical use and does not replace comprehensive drug information resources. Always consult the current prescribing information and relevant clinical guidelines before making therapeutic decisions.